Amicogen Inc is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâ€™s products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company sells its products in domestic and overseas markets.

Employees

236

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/10/26	KRW 988.00	-0.20%	154,296
01/10/26	KRW 990.00	+4.43%	243,923
30/09/26	KRW 948.00	-1.76%	152,488
29/09/26	KRW 965.00	-1.93%	238,413

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 02/10/2026			5-day change	1st Jan Change
988.00 ^KRW	-0.20%		+5.67%	-44.56%

21/09	Amicogen, Inc.(KOSDAQ:A092040) dropped from S&P Global BMI Index	CI
14/08	Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	69.61B 51.69M 45.92M 42.86M 39.07M 73.68M 4.97B 74.36M 519M 201M 2.54B 194M 190M 8.15B	P/E 2024	-4.02x	P/E 2025	-3.28x
Enterprise Value	157B 116M 103M 96.37M 87.84M 166M 11.17B 167M 1.17B 452M 5.71B 436M 427M 18.33B	EV / Sales 2024	1.86x	EV / Sales 2025	4.43x
Free-Float	95.04%	Yield 2024 *	-	Yield 2025	-

21/09	Amicogen, Inc.(KOSDAQ:A092040) dropped from S&P Global BMI Index	CI
14/08	Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
04/08	Amicogen, Inc. cancelled the transaction announced on June 22, 2026	CI
22/06	Amicogen, Inc. announced that it expects to receive KRW 9.9999989 billion in funding	CI
14/05	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/03	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
14/11	Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
22/09/25	Amicogen, Inc.(KOSDAQ:A092040) added to S&P Global BMI Index	CI
20/08/25	Bio-Works Launches WorkBeads AffimAb Edge: Strategic Expansion in the Protein A Resin Market	CI
14/08/25	Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
12/08/25	Amicogen, Inc. announced that it has received KRW 7 billion in funding from BIFIDO Co., Ltd.	CI
14/05/25	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25/04/25	Amicogen, Inc.(KOSDAQ:A092040) dropped from S&P Global BMI Index	CI

21/06/24	Bio-Works and Amicogen have concluded their technology transfer project.	AQ
10/09/21	Bio Works Technologies : Amicogen Inc enters into agreement to divest its ownership in Bio-Works	AQ
17/02/21	Bio Works Technologies : Works signs licensing agreement with Amicogen Inc to establish local manufacturing of agarose resins in South Korea	AQ

Amicogen, Inc. Stock

Stocks

A092040

KR7092040005

Biotechnology & Medical Research

Valuation: Amicogen, Inc.

Chart: Amicogen, Inc.

Latest news: Amicogen, Inc.

Press Releases: Amicogen, Inc.

News in other languages: Amicogen, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Amicogen, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 day	-0.20%
1 week	+5.67%
Current month	+4.22%
1 month	+0.20%
3 months	-26.32%
6 months	-37.11%
Current year	-44.56%

1 week	939	1,083
1 month	787	1,083
Current year	787	2,300
1 year	787	3,940
3 years	787	9,400
5 years	787	17,750
10 years	787	24,825

Manager	Title	Age	Since
Jjeo Pyo CEO	Chief Executive Officer	53	-
Young-Chul Yoon PRN	Corporate Officer/Principal	55	28/03/2024
Chun-Gu Kim AUD	Comptroller/Controller/Auditor	69	27/03/2025

Director	Title	Age	Since
Jun-Ho Kim BRD	Director/Board Member	56	26/02/2025
Jjeo Pyo BRD	Director/Board Member	53	-
Young-Chul Yoon BRD	Director/Board Member	55	28/03/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/3/26	Ji-Seong So	Buy	Director	435	0.0006%
3/3/26	Young-Chul Yoon	Buy	Director	109	0.0002%
27/2/26	Eun-seong Hwang	Buy		4,000	0.0072%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMICOGEN, INC.	-0.20%	+5.67%	-74.40%	-85.24%	51.69M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+20.19%	+81.44%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+2.17%	+36.19%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+342.39%	+742.40%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+24.96%	+35.38%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+4.13%	+105.50%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.33%	+22.72%	28.53B
BIONTECH SE	+0.05%	-1.64%	-8.14%	-11.37%	24.34B
Average	-0.22%	-0.49%	+39.93%	+107.16%	39.06B
Weighted average by Cap.	+0.12%	-0.84%	+56.94%	+138.23%

	2024	2025
Net sales	174B 129M 115M 107M 97.43M 184M 12.39B 185M 1.29B 501M 6.33B 484M 473M 20.33B	41.98B 31.17M 27.7M 25.85M 23.56M 44.44M 3B 44.85M 313M 121M 1.53B 117M 114M 4.92B
Net income	-52.79B -39.2M -34.83M -32.51M -29.63M -55.88M -3.77B -56.4M -393M -152M -1.93B -147M -144M -6.18B	-29.96B -22.25M -19.77M -18.45M -16.81M -31.71M -2.14B -32.01M -223M -86.51M -1.09B -83.52M -81.71M -3.51B
Net Debt	112B 82.8M 73.57M 68.67M 62.59M 118M 7.96B 119M 831M 322M 4.07B 311M 304M 13.06B	86.91B 64.53M 57.34M 53.51M 48.78M 91.99M 6.2B 92.85M 648M 251M 3.17B 242M 237M 10.18B